JP4340734B2 - 細胞検出方法 - Google Patents
細胞検出方法 Download PDFInfo
- Publication number
- JP4340734B2 JP4340734B2 JP2001575233A JP2001575233A JP4340734B2 JP 4340734 B2 JP4340734 B2 JP 4340734B2 JP 2001575233 A JP2001575233 A JP 2001575233A JP 2001575233 A JP2001575233 A JP 2001575233A JP 4340734 B2 JP4340734 B2 JP 4340734B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sample
- life
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001514 detection method Methods 0.000 title claims description 47
- 239000000523 sample Substances 0.000 claims description 179
- 150000007523 nucleic acids Chemical class 0.000 claims description 150
- 108020004707 nucleic acids Proteins 0.000 claims description 145
- 102000039446 nucleic acids Human genes 0.000 claims description 145
- 238000000034 method Methods 0.000 claims description 67
- 108020004414 DNA Proteins 0.000 claims description 63
- GHUXAYLZEGLXDA-UHFFFAOYSA-N 8-azido-5-ethyl-6-phenylphenanthridin-5-ium-3-amine;bromide Chemical compound [Br-].C12=CC(N=[N+]=[N-])=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 GHUXAYLZEGLXDA-UHFFFAOYSA-N 0.000 claims description 50
- 230000034994 death Effects 0.000 claims description 43
- 230000003321 amplification Effects 0.000 claims description 42
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 42
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 32
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 32
- 238000009739 binding Methods 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012163 sequencing technique Methods 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical group [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 229960005542 ethidium bromide Drugs 0.000 claims description 6
- 238000013459 approach Methods 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 230000002934 lysing effect Effects 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 4
- 239000002751 oligonucleotide probe Substances 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 230000002427 irreversible effect Effects 0.000 claims description 3
- ZJVOHJVSTORGLI-UHFFFAOYSA-N 5-Methylangelicin Chemical compound O1C(=O)C=CC2=C1C(C=CO1)=C1C=C2C ZJVOHJVSTORGLI-UHFFFAOYSA-N 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001293 nucleolytic effect Effects 0.000 claims 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 165
- 241000894006 Bacteria Species 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000975 dye Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 230000007613 environmental effect Effects 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002944 PCR assay Methods 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000002186 photoactivation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- -1 such as a DNAse Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000007826 nucleic acid assay Methods 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MXLMTQWGSQIYOW-UHFFFAOYSA-N 3-methyl-2-butanol Chemical compound CC(C)C(C)O MXLMTQWGSQIYOW-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007859 qualitative PCR Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0008787.4 | 2000-04-10 | ||
| GBGB0008787.4A GB0008787D0 (en) | 2000-04-10 | 2000-04-10 | A method of cell detection |
| PCT/GB2001/001619 WO2001077379A2 (en) | 2000-04-10 | 2001-04-10 | A method of cell detection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003530118A JP2003530118A (ja) | 2003-10-14 |
| JP2003530118A5 JP2003530118A5 (https=) | 2005-06-09 |
| JP4340734B2 true JP4340734B2 (ja) | 2009-10-07 |
Family
ID=9889587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001575233A Expired - Lifetime JP4340734B2 (ja) | 2000-04-10 | 2001-04-10 | 細胞検出方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7262009B2 (https=) |
| EP (1) | EP1272664A2 (https=) |
| JP (1) | JP4340734B2 (https=) |
| AU (2) | AU4671201A (https=) |
| CA (1) | CA2405769A1 (https=) |
| GB (1) | GB0008787D0 (https=) |
| NO (1) | NO20024879L (https=) |
| WO (1) | WO2001077379A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006007479A2 (en) * | 2004-07-01 | 2006-01-19 | Litron Laboratories, Ltd. | Method for enumerating mammalian cell micronuclei via differential staining |
| EP1918385B1 (en) | 2005-07-21 | 2011-06-29 | Morinaga Milk Industry Co., Ltd. | Method for detection of microorganism and kit for detection of microorganism |
| WO2007094077A1 (ja) | 2006-02-17 | 2007-08-23 | Kyushu University | 微生物検出法及び微生物検出キット |
| US8198040B2 (en) | 2006-02-28 | 2012-06-12 | Montana State University | Use of phenanthridium derivatives for distinguishing between live and dead cells |
| JP4113556B2 (ja) * | 2006-12-04 | 2008-07-09 | 国立大学法人九州大学 | 核酸分解剤および核酸の分解方法 |
| AU2008287928B2 (en) | 2007-08-16 | 2011-07-28 | Morinaga Milk Industry Co., Ltd. | Method and kit for detection of microorganism |
| KR101383389B1 (ko) | 2009-07-24 | 2014-04-08 | 모리나가 뉴교 가부시키가이샤 | 미생물 검출법 및 미생물 검출 키트 |
| WO2011043737A1 (en) * | 2009-10-05 | 2011-04-14 | Nanyang Technological University | Viability analysis of protozoa using polymerase chain reaction (pcr) |
| FR2974117B1 (fr) | 2011-04-18 | 2018-05-11 | Societe Des Eaux De Marseille | Procede de quantification de bacteries vivantes dans un milieu liquide |
| CA2872149C (en) | 2012-05-02 | 2019-03-19 | Charles River Laboratories, Inc. | Viability staining method |
| CN104755931B (zh) | 2012-05-02 | 2016-08-31 | 查尔斯河实验室公司 | 用于检测细胞样品中的活细胞的方法 |
| CN104685346B (zh) | 2012-05-02 | 2018-05-29 | 查尔斯河实验室公司 | 细胞捕获系统及其使用 |
| DE102020103971B4 (de) | 2020-02-14 | 2022-02-24 | Testo bioAnalytics GmbH | Verfahren zum Nachweis von lebenden Mikroorganismen und ein fluidisches Kanalsystem |
| WO2022051405A1 (en) | 2020-09-02 | 2022-03-10 | Promega Corporation | Nucleic acid modifying reagents and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0517154A1 (en) * | 1991-06-06 | 1992-12-09 | F. Hoffmann-La Roche Ag | Method for detecting giardia |
| US5314805A (en) * | 1991-10-28 | 1994-05-24 | Molecular Probes, Inc. | Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM |
| US5525471A (en) * | 1994-10-12 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enzymatic degrading subtraction hybridization |
| US20020119438A1 (en) | 1995-12-29 | 2002-08-29 | Fuminori Kato | Method for determining viable cell count |
| US5780278A (en) * | 1996-05-20 | 1998-07-14 | Vanderbilt University | IceA gene and related methods |
| GB9709728D0 (en) | 1997-05-13 | 1997-07-02 | Dynal As | Single step method |
-
2000
- 2000-04-10 GB GBGB0008787.4A patent/GB0008787D0/en not_active Ceased
-
2001
- 2001-04-10 AU AU4671201A patent/AU4671201A/xx active Pending
- 2001-04-10 US US10/257,493 patent/US7262009B2/en not_active Expired - Fee Related
- 2001-04-10 EP EP01919651A patent/EP1272664A2/en not_active Withdrawn
- 2001-04-10 JP JP2001575233A patent/JP4340734B2/ja not_active Expired - Lifetime
- 2001-04-10 AU AU2001246712A patent/AU2001246712C1/en not_active Ceased
- 2001-04-10 CA CA002405769A patent/CA2405769A1/en not_active Abandoned
- 2001-04-10 WO PCT/GB2001/001619 patent/WO2001077379A2/en not_active Ceased
-
2002
- 2002-10-09 NO NO20024879A patent/NO20024879L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003530118A (ja) | 2003-10-14 |
| AU2001246712B2 (en) | 2006-10-19 |
| US7262009B2 (en) | 2007-08-28 |
| US20030203374A1 (en) | 2003-10-30 |
| AU2001246712C1 (en) | 2007-08-02 |
| CA2405769A1 (en) | 2001-10-18 |
| AU4671201A (en) | 2001-10-23 |
| GB0008787D0 (en) | 2000-05-31 |
| NO20024879D0 (no) | 2002-10-09 |
| EP1272664A2 (en) | 2003-01-08 |
| WO2001077379A2 (en) | 2001-10-18 |
| NO20024879L (no) | 2002-12-10 |
| WO2001077379A3 (en) | 2002-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Birch et al. | A comparison of nucleic acid amplification techniques for the assessment of bacterial viability | |
| JP4340734B2 (ja) | 細胞検出方法 | |
| CN112159854B (zh) | 一种大肠杆菌O157:H7的CRISPR/Cas12a检测用引物组合物和检测方法 | |
| Perry‐O’Keefe et al. | Filter‐based PNA in situ hybridization for rapid detection, identification and enumeration of specific micro‐organisms | |
| US20220372558A1 (en) | Method and Kit of Detecting the Absence of Micro-Organisms | |
| EP3775254B1 (en) | Microorganism separation and detection | |
| JPS60501339A (ja) | 生物を検出、同定又は定量する方法およびキット | |
| Wu et al. | Trace detection of specific viable bacteria using tetracysteine-tagged bacteriophages | |
| AU2001246712A1 (en) | A method of cell detection | |
| EP3902929B1 (en) | Fast and portable microfluidic detection system as an alternative to salmonella's classical culture method | |
| JP5766216B2 (ja) | 核酸修飾方法 | |
| Lu et al. | LAMP-based method for a rapid identification of Legionella spp. and Legionella pneumophila | |
| Faggi et al. | Use of magnetic beads to extract fungal DNA | |
| Giacomazzi et al. | Comparison of three methods of DNA extraction from cold‐smoked salmon and impact of physical treatments | |
| US20260117313A1 (en) | A crispr rna for detection of burkholderia pseudomallei-associated genetic material in a biological sample and a method using the same | |
| Petershofen et al. | Detection of nucleic acid sequences from bacterial species with molecular genetic methods | |
| US20200283845A1 (en) | Microarray Based Multiplex Pathogen Analysis for Plants, Agriculture, Food, and Water | |
| CN115838786B (zh) | 一种定量活菌rna单核苷酸多态性的检测技术 | |
| EP1851325B1 (en) | Method for detecting viable cells in a sample by using a virus | |
| JP3507692B2 (ja) | ヌクレオチド配列標的アナライトの検出用集合体並びに検出及び定量方法 | |
| WO2005083114A1 (en) | Method, kit and system for enhanced nested pcr | |
| RU2738358C1 (ru) | Набор олигонуклеотидных праймеров и флуоресцентно-меченых зондов и способ выявления ДНК возбудителей сапа и мелиоидоза методом ПЦР с детекцией продукта в режиме реального времени | |
| JP2006166712A (ja) | 核酸修飾前の検体の前処理方法 | |
| WO2024048755A1 (ja) | 迅速無菌試験法 | |
| Shih et al. | Field-Compatible Detection of Spiroplasma citri Associated with Citrus Stubborn Disease Using CRISPR-Cas12a and Crude Sample Preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040506 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061024 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081021 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20081226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090512 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090604 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120717 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4340734 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120717 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120717 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130717 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |